WO1997029201A3 - Vecteur retroviral pour le transfert genique d'un antagoniste d'il6 dans des cellules souches hematopoietiques humaines - Google Patents

Vecteur retroviral pour le transfert genique d'un antagoniste d'il6 dans des cellules souches hematopoietiques humaines Download PDF

Info

Publication number
WO1997029201A3
WO1997029201A3 PCT/DE1997/000231 DE9700231W WO9729201A3 WO 1997029201 A3 WO1997029201 A3 WO 1997029201A3 DE 9700231 W DE9700231 W DE 9700231W WO 9729201 A3 WO9729201 A3 WO 9729201A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
antagonist
retroviral
suicide
vector
Prior art date
Application number
PCT/DE1997/000231
Other languages
German (de)
English (en)
Other versions
WO1997029201A2 (fr
Inventor
Ralf Bargou
Christopher Baum
Dirk Hoenemann
Original Assignee
Max Delbrueck Centrum
Ralf Bargou
Christopher Baum
Dirk Hoenemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum, Ralf Bargou, Christopher Baum, Dirk Hoenemann filed Critical Max Delbrueck Centrum
Publication of WO1997029201A2 publication Critical patent/WO1997029201A2/fr
Publication of WO1997029201A3 publication Critical patent/WO1997029201A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un vecteur rétroviral pour le transfert génique d'un antagoniste d'interleukine 6(IL6) dans des cellules souches hématopoïétiques humaines en vue du traitement du myélome multiple. Les domaines d'application de l'invention sont la médecine et l'industrie pharmaceutique. Le vecteur décrit est constitué d'un vecteur initial rétroviral, du gène d'un antagoniste d'IL6, d'un gène-suicide ou d'un gène de sélection, et éventuellement de promoteurs pour la transcription du gène-suicide ou du gène de sélection. Une forme préférée de réalisation est constituée du dérivé pLXSN de MoMLV comme vecteur initial rétroviral, du gène d'un antagoniste d'IL6 ayant muté, par rapport à l'interleukine 6 humaine, au niveau de 20 codons maximum, du gène pour la néomycine acétyl-transférase comme gène de sélection, et des promoteurs précoces immédiats viraux des virus CMV et SV40. Une autre forme de réalisation préférée est constituée du dérivé pSF1N de MoMLV comme vecteur initial rétroviral, du gène d'un antagoniste d'IL6 ayant muté, par rapport à l'interleukine 6 humaine, au niveau de 7 codons, et du gène de thymidine-kinase ou bien du gène de cytosine-désaminase comme gène-suicide ou encore du gène de puromycine ou du gène de mdr-1 comme gène de sélection.
PCT/DE1997/000231 1996-02-07 1997-01-29 Vecteur retroviral pour le transfert genique d'un antagoniste d'il6 dans des cellules souches hematopoietiques humaines WO1997029201A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604378 1996-02-07
DE19604378.6 1996-02-07

Publications (2)

Publication Number Publication Date
WO1997029201A2 WO1997029201A2 (fr) 1997-08-14
WO1997029201A3 true WO1997029201A3 (fr) 1997-10-02

Family

ID=7784718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/000231 WO1997029201A2 (fr) 1996-02-07 1997-01-29 Vecteur retroviral pour le transfert genique d'un antagoniste d'il6 dans des cellules souches hematopoietiques humaines

Country Status (2)

Country Link
DE (1) DE19704979A1 (fr)
WO (1) WO1997029201A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
GB0022101D0 (en) * 2000-09-08 2000-10-25 Phogen Ltd Delivery of substances to cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001281A1 (fr) * 1991-07-03 1993-01-21 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Systeme de selection negative de cytosine desaminase pour techniques et therapies de transfert de gene
WO1994024870A1 (fr) * 1993-01-20 1994-11-10 Biotransplant, Inc. Vecteurs retroviraux capables d'exprimer des proteines multimeres a partir de sites multiples d'initiation de traduction
WO1995032282A1 (fr) * 1994-05-19 1995-11-30 Human Genome Sciences, Inc. Variant d'epissure d'interleukine-6
WO1995034669A2 (fr) * 1994-06-02 1995-12-21 Somatix Therapy Corporation Vecteurs retroviraux de therapie genique et procedes therapeutiques correspondants
WO1996007747A1 (fr) * 1994-09-08 1996-03-14 Boehringer Mannheim Gmbh Hybrides vectoriels retroviraux et leur utilisation pour le transfert de genes
WO1996034104A1 (fr) * 1995-04-28 1996-10-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Antagonistes de l'interleukine-6 humaine totalement incapables de se lier a la gp130 et leur utilisation pour l'elaboration de composes pharmaceutiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001281A1 (fr) * 1991-07-03 1993-01-21 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Systeme de selection negative de cytosine desaminase pour techniques et therapies de transfert de gene
WO1994024870A1 (fr) * 1993-01-20 1994-11-10 Biotransplant, Inc. Vecteurs retroviraux capables d'exprimer des proteines multimeres a partir de sites multiples d'initiation de traduction
WO1995032282A1 (fr) * 1994-05-19 1995-11-30 Human Genome Sciences, Inc. Variant d'epissure d'interleukine-6
WO1995034669A2 (fr) * 1994-06-02 1995-12-21 Somatix Therapy Corporation Vecteurs retroviraux de therapie genique et procedes therapeutiques correspondants
WO1996007747A1 (fr) * 1994-09-08 1996-03-14 Boehringer Mannheim Gmbh Hybrides vectoriels retroviraux et leur utilisation pour le transfert de genes
WO1996034104A1 (fr) * 1995-04-28 1996-10-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Antagonistes de l'interleukine-6 humaine totalement incapables de se lier a la gp130 et leur utilisation pour l'elaboration de composes pharmaceutiques

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAUM C ET AL: "NOVEL RETROVIRAL VECTORS FOR EFFICIENT EXPRESSION OF THE MULTIDRUG RESISTANCE (mdr-1) GENE IN EARLY HEMATOPOIETIC CELLS", JOURNAL OF VIROLOGY, vol. 69, no. 12, December 1995 (1995-12-01), pages 7541 - 7547, XP002036889 *
CRAVCHIK A AND MATUS A: "A NOVEL STRATEGY FOR THE IMMUNOLOGICAL TAGGING OF cDNA CONSTRUCTS", GENE, vol. 137, no. 1, 1993, pages 139 - 143, XP002036890 *
HON DE F D ET AL: "DEVELOPMENT OF AN INTERLEUKIN (IL) 6 RECEPTOR ANTAGONIST THAT INHIBITS IL-6-DEPENDENT GROWTH OF HUMAN MYELOMA CELLS", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 180, no. 6, 1 December 1994 (1994-12-01), pages 2395 - 2400, XP000601681 *
KALLE VON C ET AL: "INCREASED GENE TRANSFER INTO HUMAN HEMATOPOIETIC PROGENITOR CELLS BY EXTENDED IN VITRO EXPOSURE TO A PSEUDOTYPED RETROVIRAL VECTOR", BLOOD, vol. 84, no. 9, 1 November 1994 (1994-11-01), pages 2890 - 2897, XP000196799 *
MCLACHLIN J R ET AL: "RETROVIRAL-MEDIATED GENE TRANSFER", PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, vol. 38, 1990, pages 91 - 135, XP002030826 *
MORGENSTERN J P ET AL: "ADVANCED MAMMALIAN GENE TRANSFER: HIGH TITRE RETROVIRAL VECTORS WITH MULTIPLE DRUG SELECTION MARKERS AND A COMPLEMENTARY HELPER-FREE PACKAGING CELL LINE", NUCLEIC ACIDS RESEARCH, vol. 18, no. 12, 1990, pages 3587 - 3596, XP000652091 *
SAVINO R ET AL: "RATIONAL DESIGN OF A RECEPTOR SUPER-ANTAGONIST OF HUMAN INTERLEUKIN-6", EMBO JOURNAL, vol. 13, no. 24, 1994, pages 5863 - 5870, XP000606356 *
SPORENO E ET AL: "HUMAN INTERLEUKIN-6 RECEPTOR SUPER-ANTAGONISTS WITH HIGH POTENCY AND WIDE SPECTRUM ON MULTIPLE MYELOMA CELLS", BLOOD, vol. 87, no. 11, 1 June 1996 (1996-06-01), pages 4510 - 4519, XP000612195 *

Also Published As

Publication number Publication date
WO1997029201A2 (fr) 1997-08-14
DE19704979A1 (de) 1997-08-14

Similar Documents

Publication Publication Date Title
Liu et al. Generation of mammalian cells stably expressing multiple genes at predetermined levels
AU7791991A (en) Methods for phenotype creation from multiple gene populations
AU3636189A (en) Hiv-2 virus variants
AU7117496A (en) Peptide inhibitor for viral protease derived from the transframe region of the gag-pol gene
ZA969489B (en) Novel transfection agents and their pharmaceutical applications
TR199901734T2 (xx) N�rotrofinlerin ar�t�lmas�.
AU4980397A (en) Liquid distribution system
TR199700726T1 (xx) Farnezil transferaz �nleyiciler ve m�stahzarlar�.
CA2011878A1 (fr) Regions immunogenes sur la proteine e7 du papillomavirus humain de type 16
AU7035991A (en) Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
WO1997029201A3 (fr) Vecteur retroviral pour le transfert genique d'un antagoniste d'il6 dans des cellules souches hematopoietiques humaines
MX9708792A (es) Gen de ataxia-telangiectasia.
FR2696189B1 (fr) Polypeptides impliqués dans la biosynthèse des streptogramines, séquences nucléotidiques codant pour ces polypeptides et leur utilisation.
AU6079999A (en) Gene modification in the gene for the die gbeta3-sub-unit of human g-protein
ZA938709B (en) Multifunctional neurotrophic factors
IL148360A0 (en) A herpes viral mutant and pharmaceutical compositions containing the same
PT975783E (pt) "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas"
GR3025872T3 (en) Orally active derivatives of 1,3,5(10)-estratriene
PT880594E (pt) Vector retroviral e sua utilizacao em terapia genica
AU6144294A (en) Plant virus resistance conferring polyribozyme and resistant plants producing same
Kara et al. Promoter accessibility within the environment of the MHC is affected in class II‐deficient combined immunodeficiency.
FI971377A0 (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni
WO1998018950A3 (fr) Adn de virus associe aux adenovirus comportant des sequences de virus assistant
AU2890495A (en) Nucleic acid fragments and corresponding peptide fragments from the caprine arthritis-encephalitis virus (caev) genome, and uses thereof
AU1554792A (en) Nucleotide probes and primers for genetic analysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97528051

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase